Transplantation in the onco-hematology field: Focus on the manipulation of αβ and γδ T cells

Pathology Research and Practice

Volumn 208, Issue 2, 2012, Pages 67-73

  Daniele, Nicola ^a,b   Scerpa, Maria Cristina ^a   Caniglia, Maurizio ^a   Bernardo, Maria Ester ^a   Rossi, Cecilia ^a,b   Ciammetti, Chiara ^a,b   Palumbo, Giuseppe ^a,b   Locatelli, Franco ^a,b,c   Isacchi, Giancarlo ^a,b   Zinno, Francesco ^a,b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

T cells; T cells; Allogeneic transplantation; T cell depletion

Indexed keywords

CHEMOKINE; CYTOKINE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; CYTOKINE RELEASE; CYTOLYSIS; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HEMATOLOGY; IMMUNOMAGNETIC DEPLETION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; ONCOLOGY; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; REVIEW; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CELL SURVIVAL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST VS GRAFT REACTION; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856947604     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.10.006     Document Type: Review

References (54)

1. Allison T.J., Winter C.C., Fournié J.J., Bonneville M., Garboczi D.N. Structure of a human gammadelta T-cell antigen receptor. Nature 2001, 411:820-824.
2. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N. Engl. J. Med. 1989, 320:197-204.
3. Anasetti C., Etzioni R., Petersdorf E.W., et al. Marrow transplantation from unrelated volunteer donors. Ann. Rev. Med. 1995, 46:169-179.
4. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T-cell-depleted haploidentical " three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor - mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84:3948-3955.
5. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 1998, 339:1186-1193.
6. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 2005, 23:3447-3454.
7. Barge R.M., Starrenburg C.W., Falkenburg J.H., Fibbe W.E., Marijt E.W., Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath " in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant. 2006, 37:1129-1134.
8. Beatty P.G., Mori M., Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995, 60:778-792.
9. Biron C.A., Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 2001, 13:458-464.
10. Blazar B.R., Taylor P.A., Bluestone J.A., Vallera D.A. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens. Blood 1996, 87:4463-4472.
11. Chakrabarti S., Mackinnon S., Chopra R., Kottaridis P.D., Peggs K., O'Gorman P., Chakraverty R., Marshall T., Osman H., Mahendra P., Craddock C., Waldmann H., Hale G., Fegan C.D., Yong K., Goldstone A.H., Linch D.C., Milligan D.W. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
12. Chaleff S., Otto M., Barfield R.C., et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007, 9(8):746-754.
13. Cobbold S.P., Martin G., Quin S., Waldman H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986, 323:164-166.
14. Doherty P.C. The function of gamma delta T cells. Br. J. Haematol. 1992, 81:321-324.
15. Dokun A.O., Chu D.T., Yang L., et al. Analysis of in situ NK cell responses during viral infection. J. Immunol. 2001, 167:5286-5293.
16. Douek D.C., et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000, 355:1875-1881.
17. Drobyski W.R., Majewski D., Hanson G. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs-host disease. Biol. Blood Marrow Transplant. 1999, 5:222-230.
18. Garboczi D.N., Ghosh P., Utz U., et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384:134-141.
19. Gilleece M.H., Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk. Lymphoma 2003, 44:23-28.
20. Gordon P.R., Leimig T., Mueller I., et al. A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 2002, 30:69-74.
21. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002, 100:397-405.
22. Guo B., Hollmig K., Lopez R.D. In vitro activity of apoptosis resistant human gamma delta-T cells against solid malignancies. J. Clin. Oncol. 2001, 20:267. (Abstract).
23. Handgretinger R., Klingebiel T., Lang P., et al. Megadose transplantation of purified peripheral blood CD34 (+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001, 27:777-783.
24. Hayday A., Tigelaar R. Immunoregulation in the tissues by γδ T cells. Nat. Rev. Immunol. 2003, 3:233-242.
25. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997, 89:3864-3872.
26. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
27. Kabelitz D. Function and specificity of human gamma/delta-positive T cells. Crit. Rev. Immunol. 1992, 11(5):281-303.
28. Kanda J., Chao N.J., Rizzieri D.A. Haploidentical transplantation for leukemia. Curr. Oncol. Rep. 2010, 12:292-301.
29. Keever-Taylor C.A., Wagner J.E., Kernan N.A., Small T.N., Carter S.L., Thompson J.S., Cloud G.A., Lamb L.S. Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phases II and III trial (T-cell depletion trial). Bone Marrow Transplant. 2010, 45:587-589.
30. Kernan N.A., Bartsch G., Ash R.C., et al. Retrospective analysis of 462 unrelated marrow transplants facilitated by the National Marrow Donor Program (NMDP) for treatment of acquired and congenital disorders of the lymphohematopoietic system and congenital metabolic disorders. N. Engl. J. Med. 1993, 328:593-602.
31. Kernan N.A., Flomemberg N., Dupont B., O'Reilly R.J. Graft rejection in recipients of T cell depleted HLA-nonidentical marrow transplants for leukemia: identification of host derived anti-donor allocytotoxic T lymphocytes. Transplantation 1987, 43:842-847.
32. Kreslavsky T., Gleimer M., Garbe A.I., von H., Boehmer αβ versus γδ fate choice: counting the T-cell lineages at the branch point. Immunol. Rev. 2010, 238(1):169-181.
33. Kunzmann V., Bauer E., Feurle J., et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
34. Lamb L.S., Henslee-Downey P.J., Parrish R.S., et al. Increased frequency of TCR gamma delta T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J. Hematother. 1996, 5:503-509.
35. Lamb L.S., Lopez R.D. Gamma delta T cells: a new frontier for immunotherapy?. Biol. Blood Marrow Transplant. 2005, 11(3):161-168.
36. Lamb L.S., Gee A.P., Musk P., et al. Influence of T cell depletion method on circulating gamma delta+ T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy 1999, 1:7-19.
37. Lapidot T., Lubin I., Terenzi A., et al. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc. Natl. Acad. Sci. U.S.A. 1990, 97:4595-4599.
38. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
39. Mir M.A., Battiwalla M. Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Mycopathologia 2009, 168:271-282.
40. Nanno M., Shiohara T., Yamamoto H., et al. γδ T cells: firefighters or fire boosters in the front lines of inflammatory responses. Immunol. Rev. 2007, 215:103-113.
41. O'Donnell P.V., Myers B., Edwards J., Loper K., Rhubart P., Noga S.J. CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts. Cytotherapy 2001, 3:483-488.
42. Platzbecker U., Ehninger G., Bornhauser M. Allogeneic transplantation of CD34_ selected hematopoietic cells: clinical problems and current challenges. Leuk. Lymphoma 2004, 45:447-453.
43. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94(1):333-339.
44. Russell J.H. Activation-induced death of mature T cells in the regulation of immune responses. Curr. Opin. Immunol. 1995, 7:382-388.
45. Saitoh A., Narita M., Watanabe N., et al. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med. Oncol. 2008, 25(2):137-147.
46. Schilbach K., Geiselhart A., Handgretinger R. Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 2001, 97:2917-2918.
47. Soiffer R.J., Mauch P., Tarbell N.J., et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991, 7:23-33.
48. Terenzi A., Aristei C., Chionne F., et al. Preliminary results in Fludarabin as an immunosuppressor in bone marrow transplantation conditioning. Bone Marrow Transplant. 1996, 17(Suppl. (1)):89. (Abstract).
49. Terenzi A., Lubin I., Lapidot T., et al. Enhancement of T-cell depleted bone marrow allografts in mice thiotepa. Transplantion 1990, 50:517-519.
50. Thomas E.D. Marrow transplantation for malignant disease. J. Clin. Incol. 1983, 1:517-531.
51. von dem Borne P.A., Beaumont F., Starrenburg C.W., Oudshoorn M., Hale G., Falkenburg J.H., Fibbe W.E., Willemze R., Barge R.M. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006, 91:1559-1562.
52. Watts M.J., Somervaille T.C., Ings S.J., Ahmed F., Khwaja A., Yong K., Linch D.C. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br. J. Haematol. 2002, 118:117-123.
53. Wilhelm M., Kunzmann V., Eckstein S., et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102(1):200-206.
54. Zeis M., Uharek L., Glass B., et al. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995, 59:1734-1736.